Doherty Clinical Trials to host HERACLES trial

Media Release

‍

Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to announce it has engaged a highly-regarded Australian Phase 1 Unit to deliver the upcoming HERACLES clinical trial. The trial will take place in Melbourne and will be conducted by Doherty Clinical Trials Ltd, a specialist not-for-profit organisation established by the prestigious Peter Doherty Institute for Infection and Immunity.

‍

The Doherty Clinical Trials team has wide-ranging experience working with some of the world’s leading clinical investigators and research scientists, and has a particular focus on early phase studies. It is renowned for its deep clinical trial knowledge, as well as its experience in infectious diseases and, most importantly, immunology.

‍

Doherty Clinical Trials CEO Dr Andrew Brockway said: “We are passionate about the development of new medicines for diseases with unmet medical needs and are excited to support Noxopharm through our extensive knowhow and network of collaborators.”

Noxopharm CEO Dr Gisela Mautner said: “We are very pleased to have secured such an outstanding organisation to host the HERACLES trial. The Doherty Clinical Trials team are experts in what they do, and we are looking forward to working closely with them as we take our innovative SOF-SKN™ drug for lupus into the clinic for the first time.”

‍

Peter Doherty, the patron of the Doherty Institute, has been involved in research on infection and immunity for 50 years. He won the 1996 Nobel Prize in Physiology or Medicine for discovering how the immune system recognises virus-infected cells, and was named Australian of the Year in 1997.

‍

This media release was originally published here.